FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005202783> ?p ?o ?g. }

• W3005202783 abstract "Antipsychotic medication is effective for symptomatic treatment in schizophrenia-spectrum disorders. After symptom remission, continuation of antipsychotic treatment is associated with lower relapse rates and lower symptom severity compared to dose reduction/discontinuation. Therefore, most guidelines recommend continuation of treatment with antipsychotic medication for at least 1 year. Recently, however, these guidelines have been questioned as one study has shown that more patients achieved long-term functional remission in an early discontinuation condition-a finding that was not replicated in another recently published long-term study.The HAMLETT (Handling Antipsychotic Medication Long-term Evaluation of Targeted Treatment) study is a multicenter pragmatic single-blind randomized controlled trial in two parallel conditions (1:1) investigating the effects of continuation versus dose-reduction/discontinuation of antipsychotic medication after remission of a first episode of psychosis (FEP) on personal and social functioning, psychotic symptom severity, and health-related quality of life. In total 512 participants will be included, aged between 16 and 60 years, in symptomatic remission from a FEP for 3-6 months, and for whom psychosis was not associated with severe or life-threatening self-harm or violence. Recruitment will take place at 24 Dutch sites. Patients are randomized (1:1) to: continuation of antipsychotic medication until at least 1 year after remission (original dose allowing a maximum reduction of 25%, or another antipsychotic drug in similar dose range); or gradual dose reduction till eventual discontinuation of antipsychotics according to a tapering schedule. If signs of relapse occur in this arm, medication dose can be increased again. Measurements are conducted at baseline, at 3, and 6 months post-baseline, and yearly during a follow-up period of 4 years.The HAMLETT study will offer evidence to guide patients and clinicians regarding questions concerning optimal treatment duration and when to taper off medication after remission of a FEP. Moreover, it may provide patient characteristics associated with safe dose reduction with a minimal risk of relapse.Protocol version 1.3, October 2018. The study is active and currently recruiting patients (since September 2017), with the first 200 participants by the end of 2019. We anticipate completing recruitment in 2022 and final assessments (including follow-up 3.5 years after phase one) in 2026.European Clinical Trials Database, EudraCT number 2017-002406-12. Registered 7 June 2017." @default.
• W3005202783 created "2020-02-14" @default.
• W3005202783 creator A5000594186 @default.
• W3005202783 creator A5001739218 @default.
• W3005202783 creator A5005983063 @default.
• W3005202783 creator A5007555128 @default.
• W3005202783 creator A5007639772 @default.
• W3005202783 creator A5013205325 @default.
• W3005202783 creator A5018772604 @default.
• W3005202783 creator A5020101891 @default.
• W3005202783 creator A5021165491 @default.
• W3005202783 creator A5023523511 @default.
• W3005202783 creator A5025075374 @default.
• W3005202783 creator A5026705764 @default.
• W3005202783 creator A5031803990 @default.
• W3005202783 creator A5033171571 @default.
• W3005202783 creator A5035580474 @default.
• W3005202783 creator A5036798134 @default.
• W3005202783 creator A5038349219 @default.
• W3005202783 creator A5040377390 @default.
• W3005202783 creator A5041798645 @default.
• W3005202783 creator A5049205174 @default.
• W3005202783 creator A5050674928 @default.
• W3005202783 creator A5057944911 @default.
• W3005202783 creator A5058668657 @default.
• W3005202783 creator A5059422936 @default.
• W3005202783 creator A5062084857 @default.
• W3005202783 creator A5065056337 @default.
• W3005202783 creator A5066330080 @default.
• W3005202783 creator A5067831191 @default.
• W3005202783 creator A5070417146 @default.
• W3005202783 creator A5070599133 @default.
• W3005202783 creator A5073545350 @default.
• W3005202783 creator A5074455895 @default.
• W3005202783 creator A5078388400 @default.
• W3005202783 creator A5080420784 @default.
• W3005202783 creator A5081403851 @default.
• W3005202783 creator A5083298431 @default.
• W3005202783 creator A5085646382 @default.
• W3005202783 date "2020-02-07" @default.
• W3005202783 modified "2023-10-12" @default.
• W3005202783 title "To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial" @default.
• W3005202783 cites W1518890501 @default.
• W3005202783 cites W1541013958 @default.
• W3005202783 cites W1577557314 @default.
• W3005202783 cites W1987608027 @default.
• W3005202783 cites W1994950269 @default.
• W3005202783 cites W1999689270 @default.
• W3005202783 cites W2008062633 @default.
• W3005202783 cites W2014708548 @default.
• W3005202783 cites W2019410645 @default.
• W3005202783 cites W2029935004 @default.
• W3005202783 cites W2030863659 @default.
• W3005202783 cites W2031012269 @default.
• W3005202783 cites W2032982738 @default.
• W3005202783 cites W2055799281 @default.
• W3005202783 cites W2059707463 @default.
• W3005202783 cites W2083764460 @default.
• W3005202783 cites W2083914167 @default.
• W3005202783 cites W2084518825 @default.
• W3005202783 cites W2086005584 @default.
• W3005202783 cites W2102130813 @default.
• W3005202783 cites W2103714496 @default.
• W3005202783 cites W2108696783 @default.
• W3005202783 cites W2112386737 @default.
• W3005202783 cites W2120357670 @default.
• W3005202783 cites W2124133000 @default.
• W3005202783 cites W2125616168 @default.
• W3005202783 cites W2125738714 @default.
• W3005202783 cites W2129863218 @default.
• W3005202783 cites W2131115009 @default.
• W3005202783 cites W2135169462 @default.
• W3005202783 cites W2139078690 @default.
• W3005202783 cites W2140606211 @default.
• W3005202783 cites W2142582521 @default.
• W3005202783 cites W2143025931 @default.
• W3005202783 cites W2145510285 @default.
• W3005202783 cites W2150875976 @default.
• W3005202783 cites W2156295541 @default.
• W3005202783 cites W2156547328 @default.
• W3005202783 cites W2162354029 @default.
• W3005202783 cites W2162865819 @default.
• W3005202783 cites W2165057078 @default.
• W3005202783 cites W2166023752 @default.
• W3005202783 cites W2166684116 @default.
• W3005202783 cites W2172022037 @default.
• W3005202783 cites W2229240015 @default.
• W3005202783 cites W2336417646 @default.
• W3005202783 cites W2465626299 @default.
• W3005202783 cites W2758148957 @default.
• W3005202783 cites W2789602621 @default.
• W3005202783 cites W2794673255 @default.
• W3005202783 cites W2795999196 @default.
• W3005202783 cites W2809036676 @default.
• W3005202783 cites W2810633169 @default.
• W3005202783 cites W2902014307 @default.
• W3005202783 cites W4236655469 @default.
• W3005202783 cites W4240424693 @default.
• W3005202783 cites W4367329964 @default.
• W3005202783 doi "https://doi.org/10.1186/s13063-019-3822-5" @default.

• next